Blog

Field analysis and leadership thinking for medtech sales leaders.

Looking for the full research hub, newsletter archive, and field analysis? Visit Insights.

The Coverage Calendar Belongs in Your Forecast

Soft Q4 often looks like demand failure. It is usually permission failure.

newsletterMedTechMarket AccessForecastingPipeline VelocityCommercial ExcellenceHealth Policy

Washington Is About to Grade Your Technology on Labor

Over two decades, labor productivity in US clinical care fell 1% while the rest of the service economy rose 55%. Healthcare spent $150 billion a year on IT to buy that gap. When a productivity divergence this large becomes an election issue, every technology gets sorted into two piles.

newsletterMedTechCommercial ExcellenceSales LeadershipMarket AccessHealth PolicyPipeline Velocity

What Q2 2026 Taught MedTech Leaders

Ten large medtech companies reported the June quarter. Nine raised or held full-year guidance. One cut. The difference was not the environment. It was how long it took the building to hear what the field already knew.

newsletterMedTechCommercial ExcellenceSales LeadershipPipeline VelocityForecasting

The MedTech Career: What the Numbers Actually Say

Two medical device reps. Same country, same year, same job title on the business card. One tops out around $220,000. One clears $600,000. Neither is five times better at selling. What separates the floor from the ceiling is position.

newsletterMedTechCommercial ExcellenceSales LeadershipCareer Velocity

Same Job, Different Paycheck: What Sales Careers Actually Pay in 2025-26

The range across U.S. sales roles runs from $34K to $705K. Same country, same year, same job title on a business card. Industry choice is the biggest salary decision most reps ever make.

reportcompensationsales careersmedtech

The Sales Intensity Report: What the Paycheck Doesn't Show

The compensation numbers get the attention. The intensity numbers explain them. Most reps are working harder than ever at a version of the job that was never designed to let them win.

reportsales intensitysales managementcommercial excellence

We Ran the Lab on Ourselves: Five Months of Operating a Consultancy on AI Agents

For five months we ran LiquidSMARTS℠, a healthcare commercial engineering consultancy, on AI agents and recorded everything. Here is what worked, what broke, and the guard each failure produced.

AICommercial EngineeringGovernanceCase StudyPipeline Velocity

The CFO's December Problem Is Already in Your Q3 Pipeline

A December 2026 Medicaid work-reporting deadline is already reshaping how hospital CFOs in high-exposure states evaluate every capital purchase. The rep whose ROI case still uses prior-year margins is presenting a number the CFO cannot use.

newsletterMedTechCommercial ExcellenceSales LeadershipHospital Finance

The List Gets Cut Before You Know There Was a List

When two health systems merge, two vendor lists become one. The rationalization process does not ask which product is better. It asks which supplier the combined system cannot afford to lose.

newsletterMedTechCommercial ExcellenceSales LeadershipHealthcare M&A

The CFO Already Ran the Numbers

The CFO in your next meeting has already seen the Medicaid reconciliation numbers. They have not frozen your deal because the product is wrong. They are running scenarios before they sign off on anything new.

newsletterMedTechCommercial ExcellenceSales LeadershipHealthcare Finance

The Room Was Already Full

The buyer is not more sophisticated than the rep. The buyer is more current. Those are two different problems, and the information gap between them is free to close.

newsletterMedTechCommercial ExcellenceSales LeadershipField Intelligence

What Q1 2026 Taught Commercial Leaders in MedTech

Three things defined commercial performance in medtech this quarter. None of them were product problems, and none of them close on their own.

newsletterMedTechCommercial ExcellenceSales LeadershipPipeline Velocity

The Commercial Role Is Not Disappearing. It Is Being Repriced.

AI can generate the deck, draft the business case, and summarize the literature. If that is what your commercial team does, you have a positioning problem, not a technology problem.

newsletterMedTechAISales LeadershipCommercial Excellence

The Second Proof Architecture

Clinical evidence used to be enough to close an AI deal in healthcare. It no longer is. The teams winning in 2026 have built a second proof architecture for the CIO, the CMIO, and the governance committee.

newsletterMedTechHealthcare AICommercial ExcellenceSales Enablement

Why ASC Pricing Changes Everything for Device Companies

The ambulatory surgery center shift is rewriting the economics of procedural medicine. Device companies that treat this as a facilities problem will lose to those who treat it as a commercial engineering problem.

ascmedical-devicecommercial-engineering

6 Decision-Makers. 6 Definitions of Value. 1 Deal.

Six people sit around the buying committee table. Six completely different filters. Each one can kill your deal with a single objection, and not one of them can approve it alone.

newsletterMedTechCommercial ExcellenceSales Leadership